المؤلفون: Saleh K; Department of Hematology, Gustave Roussy Cancer Campus, Villejuif 94800, France., Kordahi M; National Institute of Pathology, Baabda 1003, Lebanon., Felefly T; Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint Joseph University, Beirut 1100, Lebanon., Kourie HR; Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut 1100, Lebanon., Khalife N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France.

المصدر: Future oncology (London, England) [Future Oncol] 2022 Feb; Vol. 18 (5), pp. 519-522. Date of Electronic Publication: 2022 Jan 24.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Carcinoma, Renal Cell/*drug therapy , Immune Checkpoint Inhibitors/*therapeutic use , Kidney Neoplasms/*drug therapy, Chemotherapy, Adjuvant ; Clinical Trials as Topic ; Humans ; Immunotherapy/methods ; Nephrectomy

المؤلفون: Saleh K; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: khalil_saleh@live.com., Auperin A; Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, Villejuif, France., Martin N; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Borcoman E; Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France., Torossian N; Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France., Iacob M; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Ferrand FR; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Khalife N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Baste N; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Guigay J; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France; Paris-Saclay University, Paris, France., Daste A; Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France., Saada-Bouzid E; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France; Université Côte d'Azur, Nice, France., Even C; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Nov; Vol. 157, pp. 190-197. Date of Electronic Publication: 2021 Sep 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Immune Checkpoint Inhibitors/*therapeutic use , Squamous Cell Carcinoma of Head and Neck/*drug therapy, Adult ; Age Factors ; Aged ; Aged, 80 and over ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Middle Aged ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/mortality ; Young Adult

المؤلفون: Saleh K; Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France., Kordahi M; National Institute of Pathology, Baabda, 1003, Lebanon., Felefly T; Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon., Khalife N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

المصدر: Immunotherapy [Immunotherapy] 2021 Oct; Vol. 13 (15), pp. 1245-1247. Date of Electronic Publication: 2021 Sep 20.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Future Medicine Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE

مواضيع طبية MeSH: Standard of Care*, Antibodies, Monoclonal, Humanized/*therapeutic use , Colorectal Neoplasms/*drug therapy , Immune Checkpoint Inhibitors/*therapeutic use, Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Humans

المؤلفون: Khalife N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France., Chahine C; International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France., Kordahi M; National Institute of Pathology, Baabda, 1003, Lebanon., Felefly T; Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon., Kourie HR; Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1100, Lebanon., Saleh K; Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

المصدر: Immunotherapy [Immunotherapy] 2021 Aug; Vol. 13 (11), pp. 953-964. Date of Electronic Publication: 2021 Jun 29.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Future Medicine Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell/*drug therapy , Immune Checkpoint Inhibitors/*therapeutic use , Immunotherapy/*methods , Urinary Bladder Neoplasms/*drug therapy, Humans

المؤلفون: Saleh K; Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France., Kordahi M; Department of Pathology, National Institute of Pathology, Baabda, 1003, Lebanon., Felefly T; Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon., Kourie HR; Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon., Khalife N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

المصدر: Pharmacogenomics [Pharmacogenomics] 2021 Jul; Vol. 22 (10), pp. 587-590. Date of Electronic Publication: 2021 Jun 21.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 100897350 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8042 (Electronic) Linking ISSN: 14622416 NLM ISO Abbreviation: Pharmacogenomics Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Drug Delivery Systems/*methods , Immune Checkpoint Inhibitors/*administration & dosage , Neoplasms/*drug therapy , Proto-Oncogene Proteins p21(ras)/*antagonists & inhibitors, Acetonitriles/administration & dosage ; Drug Delivery Systems/trends ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/physiology ; Humans ; Neoplasms/genetics ; Neoplasms/metabolism ; Piperazines/administration & dosage ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism ; Pyridines/administration & dosage ; Pyrimidines/administration & dosage